CytoMed shares rise 10.10% premarket after completing T cell tech acquisition to expand cancer treatment in China, India.

CytoMed Therapeutics surged 10.10% in premarket trading following the completion of its acquisition of allogeneic gamma delta T cell technology (TCB-002) from TC BioPharm Limited, a UK-based subsidiary. The acquisition, finalized with full payment, enhances CytoMed’s platform for treating cancers in China and India, where the company aims to leverage a novel, cost-effective manufacturing approach compliant with China’s strict biological import regulations. The technology, previously in Phase I trials and granted U.S. orphan drug designation, now aligns with newly liberalized Chinese regulations (State Council Decree No. 818) streamlining cell therapy approvals. This strategic move strengthens CytoMed’s pipeline and market access, positioning it to capitalize on growing demand for affordable allogeneic immunotherapies in Asia.